Infectivity of Human Adenovirus Type 55 to Human Intestinal Cells

HE Yi-bei, WANG Wen-bo HU Zong-hai, XIONG Jie, LIU Yuan

Abstract

To examine the infectivity of human adenovirus type 55 (HAdV-55) in human intestinal cells.  Methods  Caco-2 cells were cultured in vitro, and infected with HAdV-3, 7, 14 and 55. The expression of viral proteins in infected cells was detected with immunofluorescence method. The intracellular and supernatant viral DNA levels were determined with fluorescent quantitative PCR at different points of time. The level of infectious virus particles in the supernatant of Caco-2 cells was determined with adenovirus sensitive HEp-2 infection assay.  Results  Immunofluorescence assay showed positive result for the expression of HAdV-55 virus protein in Caco-2 cells 48 h post infection. HAdV-3, 7, 14, and 55 showed sustained replication and proliferation in Caco-2 cells. The level of viral DNA in infected cells and the supernatant increased with the infection time, and the viral DNA level of HAdV-55 was significantly higher than those of HAdV-3, 7 and 14. The infectious virus particles of HAdV-55 in Caco-2 supernatant were more than those of HAdV-3, 7 and 14, showing statistically significant difference (P<0.05). Caco-2 cells were infected with low doses of virus (1×TCID50), and the cytopathic effect (CPE) of HAdV-55 infection wells was more significant than that of HAdV-3, 7 and 14 infection wells.  Conclusion  This study found that human intestinal cells were susceptible to HAdV-55, and the infection level was higher than that of other common respiratory infections caused by adenovirus types 3, 7 and 14.

 

Keywords: Adenovirus, Type 55, Intestinal cell, Infectivity, Cytopathic effect

 

Full Text:

PDF


References


LION T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev，2014，27(3): 441–462.

LYNCH J， KAJON A. Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Semin Respir Crit Care Med，2016，37(4): 586–602.

WALSH M， SETO J， JONES M， et al. Computational analysis identifies human adenovirus type 55 as a re-emergent acute respiratory disease pathogen. J Clin Microbiol，2010，48(3): 991–993.

WANG W， LIU Y， ZHOU Y， et al. Whole-genome analyses of human adenovirus type 55 emerged in Tibet, Sichuan and Yunnan in China, in 2016. PLoS One，2017，12: e0189625[2020-01-05]. https://doi.org/ 10.1371/journal.pone.0189625.

HANG J， KAJON A E， GRAF P C F， et al. Human adenovirus type 55 distribution, regional persistence, and genetic variability. Emerg Infect Dis，2020，26(7): 1497–1505.

JING S， ZHANG J， CAO M， et al. Household transmission of human adenovirus type 55 in case of fatal acute respiratory disease. Emerg Infect Dis，2019，25(9): 1756–1758.

LIU T， ZHOU Z， TIAN X， et al. A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55. Vaccine，2018， 36(16): 2199–2206.

TIAN X， JIANG Z， FAN Y， et al. A tetravalent vaccine comprising hexon-chimeric adenoviruses elicits balanced protective immunity against human adenovirus types 3, 7, 14 and 55. Antiviral Res，2018，154: 17–25.

CHOUDHRY A， MATHENA J， ALBANO J， et al. Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits. Vaccine，2016，34(38): 4558–4564.

ÇOLAK M， BOZDAYI G， ALTAY A， et al. Detection and molecular characterisation of adenovirus in children under 5 years old with diarrhoea. Turk J Med Sci，2017，47(5): 1463–1471.


Refbacks

  • There are currently no refbacks.